An interdisciplinary consortium has been established in Russia to develop radiopharmaceutical approaches for effective prostate cancer diagnostics and therapy. The consortium includes several research institutions and aims to improve the situation within the next 3 years by developing new radiopharmaceuticals and generators using technetium-99m for diagnosis and rhenium-188 for treatment. The prostate-specific membrane antigen is a focus for tracer development due to its ability to detect cancer and metastases. Improved production of the medical isotopes and optimized generator design for high specific activity are also goals of the collaboration.

1. Interdisciplinary consortium
collaboration for the development
of radiopharmaceutical approach
for effective diagnostics and
therapy of prostate cancer in Russia
• K. German1,2, O. Vlasova3, V. Petriev4, V. Skvortsov4,
G. Kodina5, A. Maruk5, N. Airapetova6, N. Epshtein6,
N. Nerozin3, A. Safonov1,2, V. Lebedev1, Ya.
Obruchnikova1,2, Yu. Shevko3
• 1 - A.N. Frumkin Institute of Physical Chemistry and Electrochemistry RAS, Moscow
• 2 - Medical Institute Reaviz, Moscow branch, Russia
• 3 - A. I. Leipunsky Institute for Physics and Power Engineering, Obninsk, Russia
• 4 - Medical Radiological Research Center of Ministry of Health of Russia, Obninsk, Russia
• 5 - Burnazyan Federal Medical Biological Center of FMBA, Moscow, Russia
• 6 - National Research Nuclear University MEPhI, Obninsk, Russia

2. Consortium organigram
Direсtorate
A.N. Frumkin
Institute of Physical
Chemistry and
Electrochemistry RAS,
Moscow
Medical
Institute Reaviz,
Moscow branch,
Russia
Burnazyan Federal
Medical Biological
Center of FMBA,
Moscow, Russia
A. I. Leipunsky Institute for
Physics and Power
Engineering, Obninsk,
Medical Radiological
Research Center of
Ministry of Health of
Russia, Obninsk, Russia
National Research
Nuclear University
MEPhI, Obninsk,
Russia
Russia
Tc-99m for
prostate cancer
diagnostics and
Re-188 for treatment

3. A.N. Frumkin Institute of Physical
Chemistry and Electrochemistry RAS,
Moscow
Technetium chemistry laboratory
• K. German, Project CEO, Head of Tc
laboratory, PhD
• A. Safonov, Deputy head of Tc laboratory, PhD
• Ya. Obruchnikova, PhD
• V. Tregubova, PhD student
• M. Glazkova
Innovation department
• V. Lebedev, General manager for innovations
Laboratory of new physical-chemical problems
• A. Tsivadze, Director of IPCE RAS, Academician
• A. Filyanin, liquid extraction group, PhD
• V. Tarasov, NMR analysis, Professor
Laboratory of substance radiation chemistry
• B. Ershov, Head of laboratory, corr. member
RAS, Professor
• E. Abkhalimov, PhD
• R. Solovov, PhD student
Laboratory of interphase boundaries and
electocatalysis
• V. Andreev, Head of laboratory, Professor
Laboratory of radioactive material analysis
• M. Grigoriev, Head of laboratory, Professor

4. Роль института в проекте
• Кто входит в проект

5. A. I. Leipunsky Institute for Physics and
Power Engineering, Obninsk, Russia
• O. Vlasova, N. Nerozin, Yu. Shevko, I. Zhuk

6. Medical Radiological Research Center
of Ministry of Health of Russia,
Obninsk, Russia
• V. Skvortsov, V. Petriev

7. National Research Nuclear University
MEPhI, Obninsk, Russia
• N. Airapetova, N. Epshtein
• Development of analytical procedures for
quality control of radiopharmaceuticals and
staff training

8. Burnazyan Federal Medical Biological
Center of FMBA, Moscow, Russia
• G. Kodina, A. Maruk
• Production of Tc-99m (for radiodiagnostics)
and Re-188 (for radiotherapy) isotopes and
preclinical medicine tests

9. Medical Institute Reaviz,
Moscow branch, Russia
• K. German, Chair of Natural science, Professor
• A. Safonov, docent, PhD
• Ya. Obruchnikova, PhD
• V. Tregubova, PhD student
• Training of medical staff for modern medicine

10. What we intend to obtain
• В ходе выполнения ПНИЭР должны быть
разработаны технологии производства генераторов
99mТс и 188Re генераторов большого номинала со
сниженным транспортным индексом, технологии
концентрирования 188Re, разработка аналитических
методик определения радиоактивных и химических
примесей в препарате 188Re, обеспечение качества
элюатов из генераторов 99mТс и 188Re в соответствии
с требованиями потенциальных
радиофармпрепаратов на их основе, специфически
связывающихся с рецепторами тканей рака
предстательной железы.

11. • Потенциальный потребитель РФП – медицинские учреждения
различных уровней, онкологические медицинские центры,
онкологические диспансеры, лицензированные для работы с
источниками ионизирующего излучения и оснащенные
диагностическим оборудованием ОФЭКТ или ПЭТ.
• Объекты применения РФП – пациенты с заболеванием РПЖ
(порядка 30 тыс. чел./год).
• За последние несколько лет в РФ регистрировалось
примерно 40 000 первичных случаев рака предстательной
железы в год, из которых, по медицинским показаниям, только
в 30% случаев проводится брахитерапия с эффективностью 75%.
• brachytherapy

12. • На сегодняшний день, существующими и
разрабатываемыми агентами (биомаркерами) для
радионуклидной визуализации РПЖ, которые
проходят клинические исследования, являются:
• 2-18F-fluoro-2-deoxy-D-glucose (FDG);
• 111In-7E11 antibody (ProstaScint);
• 18F-fluorodihydrotestosterone (18F-FDHT);
• аналоги radioacetate;
• аналоги radiocholine;
• anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic
acid (anti-[18F]FACBC).

13. Effective diagnostics and therapy of
prostate cancer is an important issue
for Russia due to constantly increasing
number of decease cases herein.
• Rational development of new radiopharmaceuticals for
the management of advanced and metastatic prostate
cancer requires an improved cooperation of the
organization thus involved. For this reason an
interdisciplinary consortium collaboration for the
development of radiopharmaceutical approach is
established with principle aim to improve the situation
within the 3 coming years.

14. • The PSMA markers are focus selection of the project
due to their ability not only for cancer but also for
methastatic object detection. Draw investigation
indicated that the prostate-specific membrane antigen
(PSMA) based markers could be the key substrate
matter for the solution of the problem. PSMA is highly
expressed in prostate cancer, and small-molecule
radiopharma-ceuticals targeting PSMA helps to rapidly
detect the location and extent of disease. Comparative
study provided with a selected row of substrates
including several MIP derivatives and some others.
Synthetic procedures were optimized for better yields,
purities and prices.

15. • Production of Tc-99m (for radiodiagnostics)
and Re-188 (for radiotherapy) isotopes were
improved with optimized generator design
aimed to high specific activity production.

16. • Special educational interdisciplinary program for specialist
training for technetium application to prostate
radiodiagnostics is elaborated.
• The development of new radiopharmaceuticals and
generators for the management of advanced prostate
cancer will help to improve the treatment of this disease in
Russia.
• Innovative character of this project requires special
attention on staff training.
• New technologies worked out by Igor Zhuk, Yury
Shevko(A.I. Leipunsky Institute for Physics and Power
Engineering, Obninsk, Russian Federation) are to be used in
this project

17. • The development of new
radiopharmaceuticals and generators for the
management of advanced prostate cancer will
help to improve the treatment of this disease
in Russia.

18. A new approach to form a
competent team of specialist
THE BASIC COMPETENCE OF
THE EXPERT AND SPECIALIST
TRAINING FOR TECHNETIUM
APPLICATION TO PROSTATE
RADIODIAGNOSTICS.

19. What makes a good specialist?
Interest Competence
Objectivity Creativity
Self-criticism
Efficiency

21. Expert assessments in Russia
• Expert assessments are applied with success
in various fields of human activity and find
their reflection in the works of such Russian
scientists as Azgaldov G.G., Beshelev S.D.,
Evlanov L.G., Gurvich F.G., Larichev O.I., Litvak
B.G., Novikov, D. A., Orlov, A.I., Raichman I.P.,
Sidelnikov Y.V., and many other authors
involved in problem of expert assessments.
21

22. Evlanov L.G. thought that the expert
has the following requirements:
1) Competence;
2) Creativity;
3) Respect to the examination;
4) Conformism;
5) Constructive thinking;
6) Teamwork;
7) Self-criticism.
22

23. In the work of Raichman A.P. and Azgldov G.G. the
quality of the expert has the following requirements:
1) Competence;
2) Interest;
3) Efficiency;
4) Objectivity.
The competence of the expert should be applied
to the object quality assessment (professional
competence) and methodology (qualitative
competence).

24. Many books are written by leading scientists,
where the expert is endowed mainly the
following qualities, namely:
1) has a degree in the subject area;
2) has a positive experience with previous
expertise in the subject area;
3) must work at least 10 years;
4) objective;
5) must constantly improve their knowledge and
so on.

25. Is it true?
In our opinion, these qualities are of a formal
nature and do not meet the full competencies
that have been proposed by the European
community as one of the core competences for
professionals of the twenty-first century.

26. The authors choose five Basic EU competencies
for the Expert of the twenty-first century :
1. Communication in the mother tongue.
2. Communication in foreign languages.
3. Mathematics skills and core competencies
(skills) in science and technology.
4. Information technology competence.
5. The ability to find new information and
produce new knowledge for expert’s
professional area.

27. Ask yourself: “Are you sure that You
have all this basic competencies?”
Or Do You think that the expert and specialist of
technetium application to prostate
radiodiagnostics do not need
this competencies?
Unfortunately, it is not simple question.
Please, think about quantity of the wrong
diagnosis in different countries

28. Data about the authors
• Zhuk Igor Aleksandrovich, PHD,
• Shevko Yuri Viktorovich,
e-mail: zz-38@yandex.ru
• (A. I. Leipunsky Institute for Physics and Power
Engineering, Obninsk, Russia)

29. Thank you
for the attention !